{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:16:26Z","timestamp":1793085386163,"version":"4.5.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Peptide receptor radionuclide therapy (PRRT) is recommended and approved in advanced neuroendocrine tumors (NETs). There is a lack of data on the utility of PRRT in multiple endocrine neoplasia (MEN) syndrome. This study explores the utility of PRRT in MEN syndrome patients with inoperable\/metastatic NETs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A single-center retrospective analysis of MEN syndrome patients with advanced NETs referred for PRRT was done. Upto 4 cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE (5.5\u20137.4\u00a0GBq\/cycle) were administered every 8\u201312 weeks. Treatment-related adverse events were assessed using CTCAE v5. The best response to PRRT was evaluated using RECIST 1.1. Follow-up was done to calculate the progression-free survival (PFS) and overall survival (OS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The data of 15 patients with a median age of 36 years (IQR: 32\u201349) was analyzed. Fourteen patients had MEN-1 syndrome, and 1 had MEN-2 syndrome. Thirteen patients with MEN-1 syndrome had gastroenteropancreatic (GEP) NET, with the multifocal primary as the most common finding (n=7). One patient had thymic carcinoid. All patients had hyperparathyroidism, while 6 had pituitary adenoma. Fifty-three cycles of <jats:sup>177<\/jats:sup>Lu-DOTATATE (range: 1\u20134) were administered with a median cumulative activity of 27.8 GBq. Twelve patients (80%) showed grade 1\/2 adverse events, with leukopenia being the most common. Six patients achieved partial response (43% ORR), 6 showed stable disease (86% DCR), 2 (14%) showed disease progression during PRRT, while 1 patient was lost to follow-up. The median PFS was 32.6 months (95% CI: 14.7\u2013not reached) with an estimated 1- and 5-year PFS rate of 86.2% (95% CI: 68\u2013100) and 46.3% (95% CI: 13\u201380), and estimated 5-year OS rate of 76.2% (95% CI: 52.1\u2013100).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>177<\/jats:sup>Lu-DOTATATE is a safe and effective treatment option for advanced NETs in MEN syndrome. However, large-sized multicentric prospective studies are required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005891","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T15:00:46Z","timestamp":1747753246000},"page":"605-611","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Peptide Receptor Radionuclide Therapy in Multiple Endocrine Neoplasia Syndrome: A Single-center Experience"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-3113","authenticated-orcid":false,"given":"Piyush","family":"Aggarwal","sequence":"first","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-6644","authenticated-orcid":false,"given":"Swayamjeet","family":"Satapathy","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjeet","family":"Kaur","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-0361","authenticated-orcid":false,"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-8778","authenticated-orcid":false,"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Walia","sequence":"additional","affiliation":[{"name":"Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-1725","authenticated-orcid":false,"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[{"name":"GI Surgery, HPB and Liver Transplantation, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0016-5783","authenticated-orcid":false,"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000511791","article-title":"At the cutting edge multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome\u2014an international consensus statement keywords multiple endocrine neoplasia type 1 \u00b7 neuroendocrine pancreatic tumors diagnosis treatment consensus statement","volume":"111","author":"Niederle","year":"2021","journal-title":"Neuroendocrinology"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"944","DOI":"10.21037\/atm-21-1165","article-title":"A narrative review of multiple endocrine neoplasia syndromes: genetics, clinical features, imaging findings, and diagnosis","volume":"9","author":"Hu","year":"2021","journal-title":"Ann Transl Med"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"T227","DOI":"10.1530\/ERC-17-0203","article-title":"Management impact: effects on quality of life and prognosis in MEN1","volume":"24","author":"Marini","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"e13343","DOI":"10.1111\/jne.13343","article-title":"European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours","volume":"35","author":"Kos-Kud\u0142a","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/ijms24021418","article-title":"The complex histopathological and immunohistochemical spectrum of neuroendocrine tumors\u2014an overview of the latest classifications","volume":"24","author":"Gheorghi\u0219an-G\u0103l\u0103\u021beanu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum Pathol"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4103\/1450-1147.203068","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and Cushing\u2019s syndrome","volume":"16","author":"Naik","year":"2017","journal-title":"World J Nucl Med"},{"key":"R11-20250619","first-page":"92","article-title":"Metastatic MEN1 syndrome treated with Lutetium-177\u2013a case report","volume":"15","author":"Gezer","year":"2019","journal-title":"Eur Endocrinol"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/jbmr.4653","article-title":"Multilevel annotation of germline MEN1 variants of synonymous, nonsynonymous, and uncertain significance in Indian patients with sporadic primary hyperparathyroidism","volume":"37","author":"Kaur","year":"2022","journal-title":"J Bone Miner Res"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/RLU.0000000000005177","article-title":"177Lu-DOTATATE salvage therapy in rapidly progressing neuroendocrine tumor with poor performance status","volume":"49","author":"Aggarwal","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1359\/jbmr.090304","article-title":"Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity","volume":"24","author":"Eller-Vainicher","year":"2009","journal-title":"J Bone Miner Res"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MD.0b013e3182954af1","article-title":"Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 men1\/zollinger-ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors","volume":"92","author":"Ito","year":"2013","journal-title":"Medicine"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/cen.13480","article-title":"Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: a single-centre study, systematic review and meta-analysis","volume":"87","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1210\/jc.2004-1155","article-title":"Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series","volume":"90","author":"Ferolla","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00268-009-0290-1","article-title":"Risk factors and causes of death in MEN1 disease. A GTE (Groupe d\u2019Etude des Tumeurs Endocrines) cohort study among 758 patients","volume":"34","author":"Goudet","year":"2010","journal-title":"World J Surg"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-10-0950","article-title":"Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d\u2019etude des Tumeurs Endocrines","volume":"165","author":"Goudet","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/RLU.0b013e318252d2c3","article-title":"Usual and unusual neuroendocrine tumor metastases on 68Ga- DOTANOC PET\/CT: a pictorial review","volume":"38","author":"Naswa","year":"2013","journal-title":"Clin Nucl Med"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1002\/ijc.30400","article-title":"The epidemiology of metastases in neuroendocrine tumors","volume":"139","author":"Riihim\u00e4ki","year":"2016","journal-title":"Int J Cancer"},{"key":"R22-20250619","first-page":"57","article-title":"Metastatic neuroendocrine pancreatic tumor\u2013case report","volume":"11","author":"Radu","year":"2018","journal-title":"J Med Life"},{"key":"R23-20250619","first-page":"131","article-title":"Spleen metastases secondary to gastric neuroendocrine carcinoma \u201ccase report\u201d","volume":"42","author":"Nasr","year":"2022","journal-title":"PAMJ"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.radcr.2021.08.033","article-title":"Splenic metastasis from neuroendocrine tumor of the stomach: a case report","volume":"16","author":"Sninate","year":"2021","journal-title":"Radiol Case Rep"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-3020-8","article-title":"Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report","volume":"17","author":"Sakuma","year":"2017","journal-title":"BMC Cancer"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2017","journal-title":"Neuroendocrinology"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2015","journal-title":"Lancet"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cen.12411","article-title":"Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours","volume":"80","author":"Ramundo","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"645","DOI":"10.21037\/jgo.2019.01.33","article-title":"The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors","volume":"10","author":"Nu\u00f1ez","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000448699","article-title":"Efficacy and long-term safety of everolimus in pancreatic neuroendocrine tumor associated with multiple endocrine neoplasia type I: case report","volume":"39","author":"Maia","year":"2016","journal-title":"Oncol Res Treat"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/GO.21.00103","article-title":"177 Lu-DOTATATE plus radiosensitizing capecitabine versus octreotide long-acting release as first-line systemic therapy in advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors: a single-institution experience","volume":"7","author":"Satapathy","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"E393","DOI":"10.1097\/RLU.0000000000003170","article-title":"Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable\/metastatic neuroendocrine tumors","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1097\/RLU.0000000000005233","article-title":"Safety and efficacy of177Lu-DOTATATE in children and young adult population: a single-center experience","volume":"49","author":"Aggarwal","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R36-20250619","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2967\/jnumed.120.244798","article-title":"18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study","volume":"62","author":"Binderup","year":"2021","journal-title":"J Nucl Med"},{"key":"R37-20250619","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [68Ga]DOTATATE and [18F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer"},{"key":"R38-20250619","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00259-020-05004-5","article-title":"Long-term outcome of \u201cSandwich\u201d chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease","volume":"48","author":"Parghane","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MNM.0000000000001350","article-title":"Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"42","author":"Kim","year":"2021","journal-title":"Nucl Med Commun"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"102203","DOI":"10.1016\/j.ctrv.2021.102203","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis","volume":"97","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/MNM.0000000000001103","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"40","author":"Satapathy","year":"2019","journal-title":"Nucl Med Commun"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","article-title":"887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol"},{"key":"R43-20250619","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:00:30Z","timestamp":1750341630000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005891","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"2025-01-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}